Pyrotinib Combined With Trastuzumab And Chemotherapy in HER2-positive MBC
NCT04609540 · Status: UNKNOWN · Type: OBSERVATIONAL · Enrollment: 200
Last updated 2020-12-16
Summary
To explore the real world data of trastuzumab Combined With Trastuzumab And Chemotherapy in China, and to explore the relationship between progression free survival and treatment pattern.
Conditions
Interventions
- DRUG
-
Dual anti-HER2 therapy
Sponsors & Collaborators
-
Shandong Cancer Hospital and Institute
lead OTHER
Eligibility
- Min Age
- 18 Years
- Max Age
- 70 Years
- Sex
- FEMALE
- Healthy Volunteers
- No
Timeline & Regulatory
- Start
- 2021-01-01
- Primary Completion
- 2021-12-01
- Completion
- 2022-06-01
More Related Trials
-
Pyrotinib, Trastuzumab And Abraxane in HER2-positive MBC With Brain Metastasis
NCT04639271 ·Status: UNKNOWN ·Phase: PHASE2
-
A Study to Evaluate Inetetamab + Pyrotinib + Chemotherapy in Previously Untreated HER2-Positive Metastatic Breast Cancer
NCT05621434 ·Status: NOT_YET_RECRUITING ·Phase: PHASE2
-
Pyrotinib in Combination With Capecitabine in Patients With Trastuzumab-resistant HER2-positive Advanced Breast Cancer
NCT04001621 ·Status: UNKNOWN ·Phase: PHASE2
-
Efficacy of Pyrotinib Plus Capecitabine in HER2-positive MBC With Active Brain Metastases That Have Failed ADCs
NCT06475443 ·Status: NOT_YET_RECRUITING ·Phase: PHASE2
-
Pyrotinib Combined With Capecitabine Metronomic Therapy in HER2-postitive Advanced Breast Cancer
NCT03923166 ·Status: UNKNOWN ·Phase: PHASE2
-
A Study of Pyrotinib Plus Capecitabine Versus Lapatinib Plus Capecitabine in Patients With HER2+Metastatic Breast Cancer Who Have Prior Received Anthracyclin, Taxane or Trastuzumab
NCT02422199 ·Status: UNKNOWN ·Phase: PHASE1/PHASE2
-
Phase II Clinical Study of T-DM1 and Pyrotinib Maleate in Patients With HER2-positive Metastatic Breast Cancer Who Had Progressed on TKI Therapy
NCT05560308 ·Status: UNKNOWN ·Phase: NA
-
A Study of Pyrotinib Plus Capecitabine Combined With SRT in HER2+ MBC With Brain Metastases
NCT05042791 ·Status: RECRUITING ·Phase: PHASE2
-
Pyrotinib Plus Vinorelbine in HER2+ Metastatic Breast Cancer Patients
NCT04517305 ·Status: COMPLETED
-
Pyrotinib Combined With Docetaxel in the First-line Treatment of HER2-positive MBC
NCT03876587 ·Status: UNKNOWN ·Phase: PHASE2
-
Inetetamab Combined With Pyrotinib and Vinorelbine as First-line to Third-line Treatment for HER2-positive Metastatic Breast Cancer
NCT05764941 ·Status: UNKNOWN
-
Study Evaluating Pyrotinib in Combination With Capecitabine In Patients With HER2 Positive Metastatic Breast Cancer
NCT02361112 ·Status: COMPLETED ·Phase: PHASE1
-
Treatment With Pyrotinib-Based Therapy in Lapatinib Resistant HER2-Positive Metastatic Breast Cancer
NCT04899128 ·Status: UNKNOWN
-
Pyrotinib Plus Vinorelbine Versus Lapatinib Plus Capecitabine
NCT04850625 ·Status: COMPLETED
-
Pyrotinib Maleate Combined With Vinorelbine in the Treatment of HER2-positive Advanced Breast Cancer
NCT04903652 ·Status: COMPLETED ·Phase: PHASE2
-
Efficacy and Safety of Inetetamab Plus Pyrotiniband and Capecitabine in HER2-positive Metastatic Breast Cancer Patients With or Without Brain Metastasis
NCT06015100 ·Status: UNKNOWN ·Phase: NA
-
Pyrotinib and Subcutaneous Preparation of Trastuzumab Combined With Capecitabine Neoadjuvant Therapy for HER2+ Study of Breast Cancer
NCT06483386 ·Status: NOT_YET_RECRUITING ·Phase: PHASE2
-
SHR-A1811 and THPy in First or Second Line for HER2 Positive Advanced Breast Cancer Brain Metastases
NCT06975475 ·Status: NOT_YET_RECRUITING ·Phase: PHASE2
-
A Study of Pyrotinib Plus Capecitabine in Patients With HER2+ Metastatic Breast Cancer
NCT02973737 ·Status: UNKNOWN ·Phase: PHASE3
-
Inetetamab Combined With Pyrotinib and Chemotherapy in the Treatment of HER2 Positive Metastatic Breast Cancer
NCT04681911 ·Status: UNKNOWN ·Phase: PHASE2
-
Pyrotinib Plus Vinorelbine in Participants With HER2-positive Previously Treated Locally Advanced or Metastatic Breast Cancer
NCT04605575 ·Status: UNKNOWN ·Phase: PHASE2
-
Inetetamab Plus Rapamycin and Chemotherapy for HER2+ Metastatic Breast Cancer With Abnormal Activation of PAM Pathway
NCT04736589 ·Status: NOT_YET_RECRUITING ·Phase: PHASE3
-
A Real-world Study of Inetetamab for First-line Treatment of MBC
NCT05980208 ·Status: NOT_YET_RECRUITING
-
This Study Aims to Optimize Neoadjuvant Therapy for HER2-positive Breast Cancer by Implementing a Dynamic Monitoring-guided Treatment Strategy.
NCT06973525 ·Status: NOT_YET_RECRUITING ·Phase: PHASE2
-
Oral Metronomic Capecitabine Combined With Pyrotinib in ADC-treated HER2-positive Metastatic Breast Cancer
NCT07019337 ·Status: NOT_YET_RECRUITING ·Phase: PHASE2